Foamy Virus
Return to Library
|
Free Foamy Virus Articles |
|
|
|
|
Research from A.V. Caprariello and co-researchers yields new findings on foamy virus
2009 MAY 11 - (NewsRx.com) -- According to recent research from the United States, "Engineered foamy virus (FV) vectors have been lauded for their superior safety profiles and stable integration patterns compared to their gammaretroviral counterparts. The drawback has been the belief that FV incorporation is cell cycle-dependent, thereby limiting its utility in post-mitotic tissues such as the central nervous system." "In this brief communication, we challenged this theory by examining FV in vivo. We injected equal titers of FV and lentivirus (LV) into the adult rat brain and found that at 1 week, FV transduced a significantly greater volume of bromodeoxyuridine (BrdU)-negative brain parenchyma than did LV. By 8 weeks, however, the volume of transduced tissue was greatly reduced-comparable to LV and restricted to BrdU+," wrote A.V. Caprariello and colleagues. The researchers concluded: "Taken together, these data implicate a role for FV in short-term gene delivery strategies to the CNS." Caprariello and colleagues published their study in Gene Therapy (Foamy virus as a gene transfer vector to the central nervous system. Gene Therapy, 2009;16(3):448-452). For additional information, contact S.M. Selkirk, VA Hospital Wade Pk, Spinal Cord Injury Division, 10701 E Blvd., Cleveland, OH 44106, USA. Publisher contact information for the journal Gene Therapy is: Nature Publishing Group, Macmillan Building, 4 Crinan St., London N1 9XW, England. Keywords: United States, Cleveland, Biotechnology, Foamy Virus, Gene Therapy, Genetics, Genomics, Treatment, Virology. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
